Close Menu

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has completed the second tranche of a previously announced $5 million placement of stock and convertible debentures.

In the new tranche, the firm sold newly registered convertible debentures, which can be converted into about 2.6 million ordinary shares, for gross proceeds of $1.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.